Inovio Pharma Q3 revenues nosedive
According to Inovio Pharmaceuticals, the decrease in the respective periods were mainly due to no revenue being recognised under the terminated Wyeth collaboration and licensing agreement as a
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.
Dalton supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. The company provides